Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forbes, Novartis deal

This article was originally published in The Tan Sheet

Executive Summary

Forbes Medi-Tech, Novartis plan to close a deal in the "very near future" resolving conflict over Master License Agreement, Forbes President & CEO Charles Butt says in Q1 conference call May 31. Firms had "very productive" meeting in May to resolve disagreement over 1999 MLA; Forbes had claimed Novartis failed to comply with MLA, said it would not pay $4 mil. to buy back Reducol rights (1"The Tan Sheet" March 25, 2002, In Brief). Butt also says Vancouver-based firm has "no immediate plans" to sell off its nutraceuticals, functional food business. In May 30 release, Forbes notes it needs "additional debt or equity financing by September 30, 2002 to meet its planned expenditures"...
Advertisement

Related Content

Reducol rights

Topics

Advertisement
UsernamePublicRestriction

Register

PS094118

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel